Lobe Sciences Ltd.
LOBEF
$0.0176
-$0.0043-19.64%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -37.78% | -- | -- |
| Gross Profit | -- | -- | -101.83% | -- | -- |
| SG&A Expenses | 7.93% | 34.46% | -57.81% | -42.98% | -21.09% |
| Depreciation & Amortization | -- | -- | -100.00% | 61.72% | 5,150.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.84% | -7.33% | -79.66% | 63.90% | -40.34% |
| Operating Income | -1.84% | -15.58% | 64.06% | -63.90% | 40.34% |
| Income Before Tax | -10.85% | -39.90% | -132.52% | -36.17% | 40.33% |
| Income Tax Expenses | -- | -- | -84.33% | -- | -- |
| Earnings from Continuing Operations | -10.85% | -39.90% | -100.21% | -36.17% | 40.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.85% | -39.90% | -100.21% | -36.17% | 40.33% |
| EBIT | -1.84% | -15.58% | 64.06% | -63.90% | 40.34% |
| EBITDA | -3.43% | -17.80% | 63.24% | -64.02% | 43.19% |
| EPS Basic | 53.57% | 35.85% | -86.15% | 0.00% | 42.27% |
| Normalized Basic EPS | 45.71% | 36.36% | 54.55% | -18.75% | 41.67% |
| EPS Diluted | 53.57% | 35.85% | -86.15% | 0.00% | 42.27% |
| Normalized Diluted EPS | 45.71% | 36.36% | 54.55% | -18.75% | 41.67% |
| Average Basic Shares Outstanding | 135.50% | 119.50% | 7.85% | 38.92% | 2.99% |
| Average Diluted Shares Outstanding | 135.50% | 119.50% | 7.85% | 38.92% | 2.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |